merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>By offering a safer, FDA-approved alternative at a lower price</answer>

<question_number>2</question_number>
<answer>By providing a direct-to-consumer telehealth platform that bypasses third-party supply chains</answer>

<question_number>3</question_number>
<answer>Lack of oversight and potential safety, quality, and effectiveness issues</answer>

<question_number>4</question_number>
<answer>To offer a cheaper alternative to its own medication, potentially attracting customers back from compounded drugs</answer>

<question_number>5</question_number>
<answer>Compounding pharmacies can legally produce copycat versions of medications listed as "in shortage" by the FDA</answer>

<question_number>6</question_number>
<answer>It reflects a trend towards transparent pricing and direct sales to consumers, bypassing traditional supply chains</answer>

<question_number>7</question_number>
<answer>Patients on Medicare might turn to cheaper alternatives like Zepbound vials due to lack of coverage for weight-loss medications</answer>

<question_number>8</question_number>
<answer>It could enhance the perception of safety by offering an FDA-approved alternative</answer>

<question_number>9</question_number>
<answer>Listed as "in shortage" by the FDA</answer>

<question_number>10</question_number>
<answer>By offering lower-priced, FDA-approved Zepbound vials</answer>